Literature DB >> 18089798

Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment.

Ann H Klopp1, Erika L Spaeth, Jennifer L Dembinski, Wendy A Woodward, Anupama Munshi, Raymond E Meyn, James D Cox, Michael Andreeff, Frank C Marini.   

Abstract

Mesenchymal stem cells (MSC) migrate to and proliferate within sites of inflammation and tumors as part of the tissue remodeling process. Radiation increases the expression of inflammatory mediators that could enhance the recruitment of MSC into the tumor microenvironment. To investigate this, bilateral murine 4T1 breast carcinomas (expressing renilla luciferase) were irradiated unilaterally (1 or 2 Gy). Twenty-four hours later, 2 x 10(5) MSC-expressing firefly luciferase were injected i.v. Mice were then monitored with bioluminescent imaging for expression of both renilla (tumor) and firefly (MSC) luciferase. Forty-eight hours postirradiation, levels of MSC engraftment were 34% higher in tumors receiving 2 Gy (P = 0.004) than in the contralateral unirradiated limb. Immunohistochemical staining of tumor sections from mice treated unilaterally with 2 Gy revealed higher levels of MSC in the parenchyma of radiated tumors, whereas a higher proportion of MSC remained vasculature-associated in unirradiated tumors. To discern the potential mediators involved in MSC attraction, in vitro migration assays showed a 50% to 80% increase in MSC migration towards conditioned media from 1 to 5 Gy-irradiated 4T1 cells compared with unirradiated 4T1 cells. Irradiated 4T1 cells had increased expression of the cytokines, transforming growth factor-beta1, vascular endothelial growth factor, and platelet-derived growth factor-BB, and this up-regulation was confirmed by immunohistochemistry in tumors irradiated in vivo. Interestingly, the chemokine receptor CCR2 was found to be up-regulated in MSC exposed to irradiated tumor cells and inhibition of CCR2 led to a marked decrease of MSC migration in vitro. In conclusion, clinically relevant low doses of irradiation increase the tropism for and engraftment of MSC in the tumor microenvironment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18089798      PMCID: PMC4329784          DOI: 10.1158/0008-5472.CAN-07-1406

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  Increased longevity of hematopoiesis in continuous bone marrow cultures and adipocytogenesis in marrow stromal cells derived from Smad3(-/-) mice.

Authors:  Michael W Epperly; Shaonan Cao; Julie Goff; Donna Shields; Shuanhu Zhou; Julie Glowacki; Joel S Greenberger
Journal:  Exp Hematol       Date:  2005-03       Impact factor: 3.084

2.  MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines.

Authors:  Christian Ries; Virginia Egea; Marisa Karow; Helmut Kolb; Marianne Jochum; Peter Neth
Journal:  Blood       Date:  2006-12-29       Impact factor: 22.113

3.  From agonist to antagonist: Fab fragments of an agonist-like monoclonal anti-beta(2)-adrenoceptor antibody behave as antagonists.

Authors:  A Mijares; D Lebesgue; G Wallukat; J Hoebeke
Journal:  Mol Pharmacol       Date:  2000-08       Impact factor: 4.436

4.  Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenoviruses.

Authors:  P Yotnda; C Zompeta; H E Heslop; M Andreeff; M K Brenner; F Marini
Journal:  Hum Gene Ther       Date:  2004-12       Impact factor: 5.695

5.  Adult bone-marrow-derived mesenchymal stem cells contribute to wound healing of skin appendages.

Authors:  Haihong Li; Xiaobing Fu; Yunshu Ouyang; Cunliang Cai; Jun Wang; Tongzhu Sun
Journal:  Cell Tissue Res       Date:  2006-08-12       Impact factor: 5.249

Review 6.  Immune modulation by ionizing radiation and its implications for cancer immunotherapy.

Authors:  Eric J Friedman
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

7.  Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors.

Authors:  Matus Studeny; Frank C Marini; Richard E Champlin; Claudia Zompetta; Isaiah J Fidler; Michael Andreeff
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

8.  Mobilization of bone marrow stem cells by granulocyte colony-stimulating factor ameliorates radiation-induced damage to salivary glands.

Authors:  Isabelle M A Lombaert; Pieter K Wierenga; Tineke Kok; Harm H Kampinga; Gerald deHaan; Robert P Coppes
Journal:  Clin Cancer Res       Date:  2006-03-15       Impact factor: 12.531

Review 9.  Recent advances into the understanding of mesenchymal stem cell trafficking.

Authors:  James M Fox; Giselle Chamberlain; Brian A Ashton; Jim Middleton
Journal:  Br J Haematol       Date:  2007-06       Impact factor: 6.998

10.  Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines.

Authors:  Tobias Birnbaum; Julia Roider; Christoph J Schankin; Claudio S Padovan; Christian Schichor; Roland Goldbrunner; Andreas Straube
Journal:  J Neurooncol       Date:  2007-02-14       Impact factor: 4.506

View more
  130 in total

1.  Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors.

Authors:  Ann H Klopp; Yan Zhang; Travis Solley; Felipe Amaya-Manzanares; Frank Marini; Michael Andreeff; Bisrat Debeb; Wendy Woodward; Rosemarie Schmandt; Russell Broaddus; Karen Lu; Mikhail G Kolonin
Journal:  Clin Cancer Res       Date:  2011-12-13       Impact factor: 12.531

2.  Homing of Mesenchymal Stem Cells.

Authors:  Reinhard Henschler; Erika Deak; Erhard Seifried
Journal:  Transfus Med Hemother       Date:  2008-07-21       Impact factor: 3.747

Review 3.  Umbilical cord-derived mesenchymal stem cells: strategies, challenges, and potential for cutaneous regeneration.

Authors:  Siming Yang; Sha Huang; Changjiang Feng; Xiaobing Fu
Journal:  Front Med       Date:  2012-03-31       Impact factor: 4.592

Review 4.  Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic.

Authors:  Jian Zhang; Lalit Patel; Kenneth J Pienta
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

5.  Enhanced homing permeability and retention of bone marrow stromal cells by noninvasive pulsed focused ultrasound.

Authors:  Ali Ziadloo; Scott R Burks; Eric M Gold; Bobbi K Lewis; Aneeka Chaudhry; Maria J Merino; Victor Frenkel; Joseph A Frank
Journal:  Stem Cells       Date:  2012-06       Impact factor: 6.277

Review 6.  Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors.

Authors:  Xiaoping Duan; Hui Guan; Ying Cao; Eugenie S Kleinerman
Journal:  Cancer       Date:  2009-01-01       Impact factor: 6.860

7.  The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells.

Authors:  Seth B Coffelt; Frank C Marini; Keri Watson; Kevin J Zwezdaryk; Jennifer L Dembinski; Heather L LaMarca; Suzanne L Tomchuck; Kerstin Honer zu Bentrup; Elizabeth S Danka; Sarah L Henkle; Aline B Scandurro
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

8.  Integral role of platelet-derived growth factor in mediating transforming growth factor-β1-dependent mesenchymal stem cell stiffening.

Authors:  Deepraj Ghosh; Loukia Lili; Daniel J McGrail; Lilya V Matyunina; John F McDonald; Michelle R Dawson
Journal:  Stem Cells Dev       Date:  2013-11-08       Impact factor: 3.272

Review 9.  Use of radionuclides in cancer research and treatment.

Authors:  M T Macías
Journal:  Clin Transl Oncol       Date:  2009-03       Impact factor: 3.405

Review 10.  Regenerative stromal cell therapy in allogeneic hematopoietic stem cell transplantation: current impact and future directions.

Authors:  Jeffery J Auletta; Kenneth R Cooke; Luis A Solchaga; Robert J Deans; Wouter van't Hof
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-16       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.